This is Psychedellux – the week’s top news for psychedelic stocks.
Tryp Therapeutics (OTCQB: TRYPF) began trading this week on the OTCQB Venture Market under the symbol “TRYPF” and will continue to trade on the Canadian Securities Exchange under the symbol “TRYP”. Last week the company appointed Greg McKee as its Chief Executive Officer.
Mydecine Innovations Group (OTC: MYCOF) has announced its four lead novel drug candidates as it prepares for its Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada. Mydecine said it believes that these drug candidates are unique and patentable in the United States and Canada and has received advice from counsel confirming such belief.
Empower Clinics Inc.(OTCQB:EPWCF) announced that patient counts increased by 460% in Q1 2021 (26,317) versus Q1 2020 (5,717). Patient counts for the month of March increased by 388% with total patient counts of 8,379 in March 2021 compared to 2,160 in March 2020.
MindMed (OTCQB: MMEDF) announced the publication of the first study on MDMA dosing optimization using personalized medicine. The dose of MDMA per kg body weight of the treated person best predicted the MDMA concentrations in the body and also mainly determined the acute subjective response to MDMA.
And finally, NeonMind Biosciences Inc. (OTC PINK: NMDBF) is starting a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions. It seems that the music a person listens to during a therapeutic trip is a major determinant of the overall experience. The first phase is an online playlist candidate validation study, surveying 50 people with relation to the self-transcendent emotions experienced when listening to snippets of longer musical tracks.
Psychedellux has been brought to you by Green Market Report.